These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 1936065)

  • 1. Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses.
    Caillé G; Boucher S; Spénard J; Lakhani Z; Russell A; Thiffault J; Grace MG
    Eur J Drug Metab Pharmacokinet; 1991; 16(1):75-80. PubMed ID: 1936065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses.
    Caillé G; Boucher S; Spénard J; Lakhani Z; Russell A; Thiffault J; Grace MG
    Eur J Drug Metab Pharmacokinet; 1991; 16(2):75-80. PubMed ID: 1936076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of diltiazem and its metabolites after repeated single dosing in healthy volunteers.
    Höglund P; Nilsson LG
    Ther Drug Monit; 1989 Sep; 11(5):551-7. PubMed ID: 2815230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter studies on the pharmacokinetic profile of sustained-release oral diltiazem (300 mg) after once a day repeated administration: influence of age.
    Bianchetti G; Billy S; Ascalone V; Saivin S; Houin G; Rosenzweig P
    Int J Clin Pharmacol Ther; 1996 May; 34(5):195-201. PubMed ID: 8738855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of diltiazem and its metabolites after single and multiple dosing in healthy volunteers.
    Höglund P; Nilsson LG
    Ther Drug Monit; 1989 Sep; 11(5):558-66. PubMed ID: 2815231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of diltiazem and propranolol when administered alone and in combination.
    Dimmitt DC; Yu DK; Elvin AT; Giesing DH; Lanman RC
    Biopharm Drug Dispos; 1991 Oct; 12(7):515-23. PubMed ID: 1932613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender related pharmacokinetics of diltiazem in healthy subjects.
    Sáenz-Campos D; Bayés MC; Martin S; Barbanoj MJ; Jané F
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):397-400. PubMed ID: 7582396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of diltiazem and its metabolites after repeated multiple-dose treatments in healthy volunteers.
    Höglund P; Nilsson LG
    Ther Drug Monit; 1989 Sep; 11(5):543-50. PubMed ID: 2815229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic interactions of moricizine and diltiazem in healthy volunteers.
    Shum L; Pieniaszek HJ; Robinson CA; Davidson AF; Widner PJ; Benedek IH; Flamenbaum W
    J Clin Pharmacol; 1996 Dec; 36(12):1161-8. PubMed ID: 9013374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single and multiple oral dose pharmacokinetics of clentiazem in normal volunteers.
    Bhargava VO; Shah AK; Weir SJ; Nordbrock EE; Giesing DH
    J Clin Pharmacol; 1993 May; 33(5):439-43. PubMed ID: 8331200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of diltiazem in patients with liver cirrhosis.
    Kurosawa S; Kurosawa N; Owada E; Soeda H; Ito K
    Int J Clin Pharmacol Res; 1990; 10(6):311-8. PubMed ID: 2099357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of pharmacokinetics, bioavailability and dose linearity of diltiazem in healthy volunteers.
    Hutt V; Janik F; Kappler J; Pabst G; Ravelli V; Maccari M; Jaeger H
    Arzneimittelforschung; 1993 Jul; 43(7):737-43. PubMed ID: 8369005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence and relative bioavailability of a new diltiazem sustained release formulation.
    Scheiwe MW; Lankhaar G; Kleinbloesem CH
    Arzneimittelforschung; 1996 Oct; 46(10):960-3. PubMed ID: 8931888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of a novel diltiazem HCl extended-release tablet formulation for evening administration.
    Sista S; Lai JC; Eradiri O; Albert KS
    J Clin Pharmacol; 2003 Oct; 43(10):1149-57. PubMed ID: 14517197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolite inhibition of parent drug biotransformation. Studies of diltiazem.
    Tsao SC; Dickinson TH; Abernethy DR
    Drug Metab Dispos; 1990; 18(2):180-2. PubMed ID: 1971570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers.
    Schulz HU; Schürer M; Bässler D; Weiser D
    Arzneimittelforschung; 2005; 55(10):561-8. PubMed ID: 16294501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives.
    Montamat SC; Abernethy DR
    Br J Clin Pharmacol; 1987 Aug; 24(2):185-9. PubMed ID: 3620292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative pharmacokinetics and pharmacodynamics of two marketed bid formulations of diltiazem in healthy volunteers.
    Guimont S; Landriault H; Klischer K; Grace M; Lambert C; Caillé G; Gossard D; Russell A; Raymond M; Hutchings E
    Biopharm Drug Dispos; 1993 Dec; 14(9):767-78. PubMed ID: 8298070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steady-state pharmacokinetics of high-dose diltiazem hydrochloride (Cardizem CD) administered once daily in healthy volunteers.
    Robbins-Weilert DK; Giesing DH; Weir SJ
    Am J Ther; 1999 Jul; 6(4):211-6. PubMed ID: 11329099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of cinnarizine after single and multiple dosing in healthy volunteers.
    Castañeda-Hernández G; Vargas-Alvarado Y; Aguirre F; Flores-Murrieta FJ
    Arzneimittelforschung; 1993 May; 43(5):539-42. PubMed ID: 8328998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.